MIRA Pharmaceuticals, Inc. Preferred Stock Dividends, Income Statement Impact
MIRA Pharmaceuticals, Inc. (MIRA) reported Preferred Stock Dividends, Income Statement Impact of $21.56 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2026-03-31
- MIRA Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-12-31 was $0.00.
- MIRA Pharmaceuticals, Inc. preferred stock dividends, income statement impact for the quarter ending 2025-09-30 was $21.56M.
- MIRA Pharmaceuticals, Inc. preferred stock dividends, income statement impact for fiscal 2025 was $21.56M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $21.56M derived: sum of 2 quarters · filed 2026-03-31 | $21.56M 10-K · filed 2026-03-31 | |
| 2025-09-30 | $21.56M 10-Q · filed 2025-11-13 | $21.56M 10-Q · filed 2025-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B |